Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine

Elad Sharon, Ronan Joseph Kelly, Eva Szabo

Research output: Contribution to journalArticle

Abstract

Background. Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis. Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy. We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine. Case presentation. A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy. Multiple metastases to bone were documented one year later. Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of disease control for over 2 years. Conclusion. This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy. In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.

Original languageEnglish (US)
Article number12
JournalHead and Neck Oncology
Volume2
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Pleomorphic Adenoma
Carcinoma
zoledronic acid
Combination Drug Therapy
Therapeutics
Salivary Gland Neoplasms
Neoplasms
Positron-Emission Tomography
Trastuzumab
Capecitabine
Radiotherapy
Immunohistochemistry
Maintenance
Clinical Trials
Neoplasm Metastasis
Bone and Bones

ASJC Scopus subject areas

  • Oncology
  • Otorhinolaryngology
  • Medicine(all)

Cite this

Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. / Sharon, Elad; Kelly, Ronan Joseph; Szabo, Eva.

In: Head and Neck Oncology, Vol. 2, No. 1, 12, 2010.

Research output: Contribution to journalArticle

Sharon, Elad ; Kelly, Ronan Joseph ; Szabo, Eva. / Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. In: Head and Neck Oncology. 2010 ; Vol. 2, No. 1.
@article{d7aa1a34b2274855823c5ba798864877,
title = "Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine",
abstract = "Background. Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis. Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy. We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine. Case presentation. A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy. Multiple metastases to bone were documented one year later. Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of disease control for over 2 years. Conclusion. This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy. In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.",
author = "Elad Sharon and Kelly, {Ronan Joseph} and Eva Szabo",
year = "2010",
doi = "10.1186/1758-3284-2-12",
language = "English (US)",
volume = "2",
journal = "Head and Neck Oncology",
issn = "1758-3284",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine

AU - Sharon, Elad

AU - Kelly, Ronan Joseph

AU - Szabo, Eva

PY - 2010

Y1 - 2010

N2 - Background. Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis. Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy. We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine. Case presentation. A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy. Multiple metastases to bone were documented one year later. Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of disease control for over 2 years. Conclusion. This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy. In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.

AB - Background. Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis. Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy. We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine. Case presentation. A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy. Multiple metastases to bone were documented one year later. Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of disease control for over 2 years. Conclusion. This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy. In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.

UR - http://www.scopus.com/inward/record.url?scp=77953952160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953952160&partnerID=8YFLogxK

U2 - 10.1186/1758-3284-2-12

DO - 10.1186/1758-3284-2-12

M3 - Article

C2 - 20504363

AN - SCOPUS:77953952160

VL - 2

JO - Head and Neck Oncology

JF - Head and Neck Oncology

SN - 1758-3284

IS - 1

M1 - 12

ER -